Comparative Pharmacology
Head-to-head clinical analysis: BETA 2 versus VOLMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETA 2 versus VOLMAX.
BETA-2 vs VOLMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP, leading to bronchodilation and inhibition of mast cell mediator release.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP, leading to bronchodilation.
2.5 mg via nebulization every 4-6 hours as needed for bronchospasm; or 90 mcg (2 inhalations) via metered-dose inhaler every 4-6 hours.
Adults: 4-8 mg orally every 12 hours (sustained-release); maximum 16 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life of 3-6 hours; clinical context: requires frequent dosing (every 4-6 hours) for sustained bronchodilation.
Terminal elimination half-life: 4-6 hours. Clinical context: requires twice-daily dosing in asthma.
Primarily renal excretion of unchanged drug and sulfate conjugates; 60-70% as unchanged drug, 15-20% as sulfate metabolites, minor biliary/fecal elimination (<5%).
Renal: 60-70% (unchanged and metabolites); fecal: 15-25%; biliary: <5%.
Category C
Category C
Beta-2 Agonist
Beta-2 Agonist